Aurinia Pharmaceuticals' (AUPH) Voclosporin Phase 2b AURA-LV Study Meets Primary Endpoint in Lupus Nephritis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/20/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Jabil falls after placing CEO on paid leave amid internal investigation
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- NVIDIA (NVDA) Shares Extend Drop To 10%, Erasing $212 Billion In Value - Bloomberg
- Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
- Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Aurinia Pharmaceuticals' (AUPH) Price Target Raised to $10 at H.C. Wainwright
August 17, 2016 9:00 AM EDTH.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals (NASDAQ: AUPH) and raised its price target to $10.00 (from $7.00). Comments follow the release of AURA-LV trial earlier this week.
Analyst Ed Arce said investors focused only on the number of deaths, and appeared to attribute them largely to voclosporin, in spite of the natural history of the... More
Aurinia Pharmaceuticals's (AUPH) Outperform Rating Reiterated at FBR Following AURA-LV Phase IIb Data
August 15, 2016 10:58 AM EDTFBR Capital reiterated an Outperform rating on Aurinia Pharmaceuticals (NASDAQ: AUPH). Shares declined after the company announced results from the AURA-LV Phase IIb clinical study with voclosporin in lupus nephritis (LN) patients. Analyst Vernon T. Bernardino sees top line results as a positive.
"We think the consensus view had... More
